Zacks Research Analysts Boost Earnings Estimates for Agios Pharmaceuticals, Inc. (NASDAQ:AGIO)

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) – Equities researchers at Zacks Research increased their Q2 2024 earnings per share (EPS) estimates for shares of Agios Pharmaceuticals in a research note issued to investors on Monday, May 20th. Zacks Research analyst A. Chakraborty now anticipates that the biopharmaceutical company will earn ($1.59) per share for the quarter, up from their prior forecast of ($1.65). The consensus estimate for Agios Pharmaceuticals’ current full-year earnings is ($4.60) per share. Zacks Research also issued estimates for Agios Pharmaceuticals’ Q3 2024 earnings at ($1.45) EPS, Q4 2024 earnings at ($1.53) EPS, FY2024 earnings at ($6.01) EPS, Q1 2025 earnings at ($1.41) EPS, Q2 2025 earnings at ($1.49) EPS, Q3 2025 earnings at ($1.40) EPS, Q4 2025 earnings at ($1.51) EPS, FY2025 earnings at ($5.80) EPS, Q1 2026 earnings at ($1.28) EPS and FY2026 earnings at ($4.89) EPS.

Several other analysts also recently commented on the stock. Cantor Fitzgerald restated an “overweight” rating on shares of Agios Pharmaceuticals in a report on Tuesday, April 9th. Royal Bank of Canada reduced their price objective on Agios Pharmaceuticals from $43.00 to $42.00 and set an “outperform” rating for the company in a research report on Friday, February 16th. JPMorgan Chase & Co. cut their target price on Agios Pharmaceuticals from $31.00 to $30.00 and set a “neutral” rating on the stock in a research note on Friday, February 23rd. The Goldman Sachs Group raised their price target on shares of Agios Pharmaceuticals from $29.00 to $33.00 and gave the stock a “neutral” rating in a research note on Friday, May 3rd. Finally, StockNews.com downgraded shares of Agios Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Tuesday. One analyst has rated the stock with a sell rating, two have assigned a hold rating and two have issued a buy rating to the company. According to MarketBeat.com, the stock has an average rating of “Hold” and a consensus price target of $35.00.

Agios Pharmaceuticals Stock Down 2.2 %

Shares of AGIO stock opened at $32.69 on Wednesday. Agios Pharmaceuticals has a 12-month low of $19.80 and a 12-month high of $35.50. The firm has a fifty day moving average of $31.11 and a 200-day moving average of $26.84. The firm has a market capitalization of $1.86 billion, a price-to-earnings ratio of -5.17 and a beta of 0.81.

Agios Pharmaceuticals (NASDAQ:AGIO) last announced its quarterly earnings results on Thursday, May 2nd. The biopharmaceutical company reported ($1.45) EPS for the quarter, beating analysts’ consensus estimates of ($1.65) by $0.20. Agios Pharmaceuticals had a negative return on equity of 41.41% and a negative net margin of 1,199.26%. The company had revenue of $8.19 million during the quarter, compared to analysts’ expectations of $8.37 million. During the same period in the prior year, the business posted ($1.47) EPS. Agios Pharmaceuticals’s revenue was up 46.0% on a year-over-year basis.

Insider Buying and Selling

In other Agios Pharmaceuticals news, Director Jacqualyn A. Fouse sold 7,791 shares of the firm’s stock in a transaction that occurred on Wednesday, April 10th. The stock was sold at an average price of $27.55, for a total value of $214,642.05. Following the completion of the transaction, the director now directly owns 137,396 shares in the company, valued at $3,785,259.80. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. In other Agios Pharmaceuticals news, Director Jacqualyn A. Fouse sold 7,791 shares of the company’s stock in a transaction on Wednesday, April 10th. The shares were sold at an average price of $27.55, for a total transaction of $214,642.05. Following the sale, the director now directly owns 137,396 shares of the company’s stock, valued at $3,785,259.80. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider James William Burns sold 2,642 shares of Agios Pharmaceuticals stock in a transaction dated Tuesday, March 5th. The shares were sold at an average price of $32.57, for a total transaction of $86,049.94. Following the completion of the transaction, the insider now directly owns 34,518 shares of the company’s stock, valued at approximately $1,124,251.26. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 14,889 shares of company stock worth $445,716. Corporate insiders own 4.93% of the company’s stock.

Hedge Funds Weigh In On Agios Pharmaceuticals

A number of institutional investors have recently bought and sold shares of AGIO. Quest Partners LLC acquired a new position in shares of Agios Pharmaceuticals during the 4th quarter worth approximately $41,000. China Universal Asset Management Co. Ltd. raised its position in shares of Agios Pharmaceuticals by 352.7% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 6,469 shares of the biopharmaceutical company’s stock valued at $144,000 after purchasing an additional 5,040 shares during the period. NEOS Investment Management LLC acquired a new stake in shares of Agios Pharmaceuticals during the 4th quarter worth about $210,000. Headlands Technologies LLC boosted its holdings in shares of Agios Pharmaceuticals by 31.3% during the 3rd quarter. Headlands Technologies LLC now owns 9,037 shares of the biopharmaceutical company’s stock worth $224,000 after buying an additional 2,153 shares during the period. Finally, Zurcher Kantonalbank Zurich Cantonalbank raised its holdings in Agios Pharmaceuticals by 9.0% in the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 11,444 shares of the biopharmaceutical company’s stock valued at $255,000 after acquiring an additional 942 shares during the period.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.